Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Niagen IV and injections perfectly align NAD+-boosting science with iCRYO’s mission to deliver solutions for recovery, performance, and healthy aging

LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that pharmaceutical-grade Niagen Plus™ products, Niagen IV and injections, are now offered at more than 50 iCRYO locations across the U.S., bringing availability to more than 900 clinics nationwide. The partnership aligns Niagen Bioscience’s innovative, science-backed, pharmaceutical-grade NAD+-boosting Niagen products with iCRYO’s clientele, who seek accessible, preventative solutions to maintain long-term health and vitality.

“Niagen IV is now offered at over 900 clinics nationwide, including the new iCRYO locations,” stated Rob Fried, CEO of Niagen Bioscience. “This milestone highlights the growing recognition of Niagen IV and injections as essential tools for supporting healthspan.”

Niagen, Niagen Bioscience’s patented nicotinamide riboside (NR) ingredient, is the most efficient and high-quality NAD+ booster available orally as Tru Niagen^®, and as IV and injectable products as Niagen Plus. A coenzyme vital to cellular health, NAD+ is essential for energy, DNA repair, and metabolism; however, levels decline with age and stress. While NAD+ decline has been associated with changes in health and vitality, research demonstrates that restoring NAD+ improves cellular function, metabolic health, and markers of aging.

“We are thrilled to partner with Niagen Bioscience, a global leader in NAD+ research and innovation, to bring their clinically proven Niagen Plus products to iCRYO centers everywhere,” said Kyle Jones, CEO and Co-founder of iCRYO. “This collaboration aligns with our mission to elevate the standard of health, wellness, and longevity globally through cutting-edge solutions that are increasingly more effective and efficient. With Niagen, we are equipping our franchisees and serving our guests with the very best.”

Outperforming NAD+ IV in a pilot clinical study, Niagen IV offers superior tolerability, a 75% shorter infusion time (30-45 minute infusion time for Niagen IV vs several hour infusion time for NAD+ IV), and results in a statistically significant 20% increase in whole blood NAD+ levels three hours post-infusion, as measured by NAD+ dried blood spot tests (MedRxiv). Because NAD+ is not bioavailable and cannot effectively raise NAD+ levels in the body, supplementing with NAD+ itself is not recommended. Furthermore, oral or intravenous NAD+ supplementation has not been well studied in humans, and its safety and efficacy remain unproven. Pharmaceutical-grade Niagen NR is the only clinically validated intravenous solution available for supporting NAD+.

Phil Singer, DO, MBA, FACEP, Chief Medical Officer of iCRYO, commented, “As a physician, I understand the profound impact of NAD+ on cellular function and overall health. Niagen Bioscience’s scientifically validated products, backed by some of the greatest researchers and innovators in the industry, provide our guests with a powerful tool to enhance energy, support metabolic health, and promote longevity, perfectly complementing our commitment to evidence-based solutions. That is why I am personally excited to introduce Niagen into iCRYO’s medical offerings across all our centers.”

By reaching over 900 clinics, including more than 50 iCRYO centers, Niagen Plus enhances nationwide access to clinically validated NAD+-boosting therapies for those seeking to improve cellular health and overall well-being.

To learn more about Niagen IV and injections at iCRYO, visit www.icryo.com. Go to www.niagenplus.com to sign up for product news and updates on future clinic availability and use the store locator function to find a clinic offering Niagen Plus therapies near you.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically proven product portfolio is Niagen^® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen^®, the number one NAD+ boosting oral supplement in the United States^† (available at www.truniagen.com), and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

^†Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024).

About iCRYO

Founded in 2015, iCRYO’s mission is to elevate the quality of life of its team members, guests, and franchisees by providing affordable, professional, and convenient personal health services while raising the standard as a global wellness brand. To learn more about its services, locations, and franchise opportunities, visit www.icryo.com.

Forward Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described. These risks and uncertainties include, but are not limited to, the scientific, regulatory, and commercial challenges inherent in dietary supplements and healthy-aging research; the acceptance of the Company’s products and educational initiatives; the outcome of ongoing or future clinical studies; protection of intellectual property; competition; and other risks described in Niagen Bioscience’s filings with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251001207600/en/

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Public Relations & Communications

(310) 405-5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

ICR, LLC

Reed Anderson

(646) 277-1260

Stephanie Carrington

(646) 277-1282

niagenir@icrinc.com

iCRYO Media Contact:

Robbie Jenkins, Director of Communications

robbie.jenkins@icryo.com

Source: Niagen Bioscience, Inc